<--- Back to Details
First PageDocument Content
Respiratory therapy / Combination drugs / Phenols / Alcohols / Glucocorticoids / Formoterol / Salmeterol / Beta2-adrenergic agonist / Long-acting beta-adrenoceptor agonist / Budesonide/formoterol / Asthma / Fluticasone propionate/salmeterol
Date: 2015-11-26 05:25:59
Respiratory therapy
Combination drugs
Phenols
Alcohols
Glucocorticoids
Formoterol
Salmeterol
Beta2-adrenergic agonist
Long-acting beta-adrenoceptor agonist
Budesonide/formoterol
Asthma
Fluticasone propionate/salmeterol

European Respiratory Disease Volume 8 • Issue 1 • Spring 2012 • Extract Improved Localised Lung Delivery Using

Add to Reading List

Source URL: www.circassia.com

Download Document from Source Website

File Size: 896,72 KB

Share Document on Facebook

Similar Documents

EZ-SCREEN® CUP Package Insert-II  The EZ-SCREEN® Cup products are rapid qualitative screening assays for the detection of any combination of the following drugs or their metabolites in human urine: Amphetamine, Barbitu

EZ-SCREEN® CUP Package Insert-II The EZ-SCREEN® Cup products are rapid qualitative screening assays for the detection of any combination of the following drugs or their metabolites in human urine: Amphetamine, Barbitu

DocID: 1vnGd - View Document

SCUDEM 2017 Problem B - Drug Interactions Patients undergoing medical treatment may be given a combination of drug therapies, and the information about the interaction between drugs can be limited[1]. One commonly prescr

SCUDEM 2017 Problem B - Drug Interactions Patients undergoing medical treatment may be given a combination of drug therapies, and the information about the interaction between drugs can be limited[1]. One commonly prescr

DocID: 1uSqq - View Document

Case 3:16-cvDocument 1 FiledPage 1 ofDorian S. Berger, CA State Bar NoDaniel P. Hipskind, CA State Bar No

Case 3:16-cvDocument 1 FiledPage 1 ofDorian S. Berger, CA State Bar NoDaniel P. Hipskind, CA State Bar No

DocID: 1rqYi - View Document

As at AugustAstraZeneca’s Environmental Risk Summaries As part of AstraZeneca’s ongoing commitment to environmental data transparency, this website provides environmental risk summaries for the Active Pharmace

As at AugustAstraZeneca’s Environmental Risk Summaries As part of AstraZeneca’s ongoing commitment to environmental data transparency, this website provides environmental risk summaries for the Active Pharmace

DocID: 1rlq4 - View Document

EISAI AND PIQUR SIGN LANDMARK COLLABORATION AGREEMENT TO INVESTIGATE HALAVEN® (ERIBULIN) AND PQR309 IN HARD TO TREAT FORM OF BREAST CANCER Agreement will see eribulin used in combination with novel PI3K/mTOR inhibitor i

EISAI AND PIQUR SIGN LANDMARK COLLABORATION AGREEMENT TO INVESTIGATE HALAVEN® (ERIBULIN) AND PQR309 IN HARD TO TREAT FORM OF BREAST CANCER Agreement will see eribulin used in combination with novel PI3K/mTOR inhibitor i

DocID: 1rhhk - View Document